The Association Between Tirzepatide Versus Insulin Glargine and NT-proBNP Levels in People With Type 2 Diabetes With or at Elevated Risk for Cardiovascular Disease: Post hoc Analyses of SURPASS 4

Naveed Sattar

School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom

Govinda J. Weerakkody

From Baylor University Medical Center, Dallas (M.P.); Imperial College, London (M.P.); RHJ Department of Veterans Affairs, Health System and Medical University of South Carolina, Charleston (M.R.Z., S.E.L.); the Cardiovascular Division, Department of Medicine, University of Virginia Health System, Charlottesville (C.M.K.); Flourish Research, Boca Raton, FL (S.J.B.); the Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland (V.M.); the Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China (J.G.); Eli Lilly, Indianapolis (G.J.W., Y.O., M.C.B., K.C.H., M.M.); and the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (B.A.B.).

Darren K. McGuire

University of Texas Southwestern Medical Center, Dallas

Mikhail N. Kosiborod

Saint Luke’s Hospital of Kansas City, Kansas (M.N.K.).

Matthew M.Y. Lee

School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom (C.J.C., M.M.Y.L.).

Paul Welsh

School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK (N.S., P.W.).

Ewan R. Pearson

Russell J. Wiese

Eli Lilly, Indianapolis

Kevin Duffin

Eli Lilly and Company, Indianapolis, IN (G.J.W., R.J.W., K.D., J.W., I.P.).

Jonathan Wilson

School of Biological Sciences, Monash University

Noemi Pavo

Martin Hülsmann

Imre Pavo

Eli Lilly, Indianapolis